Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W3UV
|
|||
| Former ID |
DNCL002156
|
|||
| Drug Name |
ABI-009
|
|||
| Indication | Malignant perivascular epithelioid cell tumour [ICD-11: 2B5Y] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [2] | ||
| Non-muscle invasive bladder cancer [ICD-11: 2C94; ICD-10: C67, C67.9; ICD-9: 188] | Phase 1/2 | [1] | ||
| Pulmonary arterial hypertension [ICD-11: BB01.0; ICD-9: 416] | Phase 1 | [3] | ||
| Company |
Celgene
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02494570) A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.